Training | 2019.12.02
Translational Study Demonstrates Value of MSOT Imaging for the Assessment of Disease Progression in Duchenne Muscular Dystrophy
A translational study conducted at the University Hospital Erlangen and published in Nature Medicine demonstrates that Multispectral Optoacoustic Tomography (MSOT), an imaging technology developed by the Munich-based company iThera Medical, can be used to visualize and quantify changes in tissue composition associated with the progression of the rare muscle disease Duchenne Muscular Dystrophy (DMD). While the established clinical outcome measures largely rely on physiological and functional tests, MSOT imaging can be an objective modality to quantify the amount of muscular fibrosis, thereby potentially providing a non-invasive and more objective measurement of disease progression and treatment response.
(PRWeb December 02, 2019)
Read the full story at https://www.prweb.com/releases/translational_study_demonstrates_value_of_msot_imaging_for_the_assessment_of_disease_progression_in_duchenne_muscular_dystrophy/prweb16715558.htm
For more information, please visit
https://www.prweb.com/releases/translati[...]ar_dystrophy/prweb16715558.htm
